GEMCITABINE HYDROCHLORIDE | A210383 | INGENUS PHARMACEUTICALS LLC
No patent or exclusivity listings for this strength.
Applicant for gemcitabine hydrochloride NDA 210383 changed from Novast Labs to Ingenus Pharms LLC.
Old: NOVAST LABS
New: INGENUS PHARMS LLC
INGENUS PHARMACEUTICALS LLC replaced NOVAST LABORATORIES LTD as the applicant for gemcitabine hydrochloride (NDA 210383, supplement 003).
Old: NOVAST LABORATORIES LTD
New: INGENUS PHARMACEUTICALS LLC
NOVAST LABS transferred NDA 210383 for Gemcitabine Hydrochloride to INGENUS PHARMS LLC, which becomes the new applicant of record.
Old: NOVAST LABS
New: INGENUS PHARMS LLC
INGENUS PHARMACEUTICALS LLC replaced NOVAST LABORATORIES LTD as the applicant for Gemcitabine Hydrochloride NDA 210383.
Old: NOVAST LABORATORIES LTD
New: INGENUS PHARMACEUTICALS LLC
INGENUS PHARMS LLC became the applicant for gemcitabine hydrochloride NDA 210383 following a transfer from NOVAST LABS.
Old: NOVAST LABS
New: INGENUS PHARMS LLC
INGENUS PHARMACEUTICALS LLC acquired applicant responsibility for Gemcitabine Hydrochloride NDA 210383 from NOVAST LABORATORIES LTD.
Old: NOVAST LABORATORIES LTD
New: INGENUS PHARMACEUTICALS LLC